{"url_path":"/sec/ltrn/8-k/2026-05-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023200-index.html","accession_number":"0001493152-26-023200","cik":"0001763950","ticker":"LTRN","issuer_name":"Lantern Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023200-index.html","primary_entity_key":"0001763950","primary_entity_name":"Lantern Pharma Inc."},"word_count":212,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n \n\nOn\nMay 13, 2026, the Company announced, by way of the press release attached hereto as Exhibit 99.1, the pricing of the offering described\nabove and plans to create an independent business entity composed of the AI platform, withZeta.ai, and related technologies and personnel\nunder the leadership of CEO Mr. Panna Sharma. The Company intends to separate its public facing AI technology assets into an independent\nbusiness entity in order to access dedicated funding sources and potentially realize valuation multiples separate from its primary drug\ndevelopment operations, which such entity may potentially become a newly listed company on a national stock exchange or market. The Company\nplans on hosting a separate investor webinar and meeting to provide additional details in the coming month.\n\n \n\nOn\nMay 12, 2026, the Company suspended offers and sales of the shares of Common Stock pursuant to the prospectus supplement, dated July\n3, 2025, relating to the ATM Sales Agreement, dated July 3, 2025 (the “Sales Agreement”), by and between the Company and\nThinkEquity LLC. The Company will not make any sales of shares of Common Stock pursuant to the Sales Agreement unless and until a new\nprospectus supplement is filed with the SEC; however, the Sales Agreement remains in full force and effect."}